ObsEva (OBSV) said on Thursday that data from its proof-of-c...

In a phase 2a study, ebopiprant was found to be well tolerated and has shown early evidence of efficacy. The statement said that compared to using Atosiban alone, the candidate drug for injecting premature women with atosiban reduced the delivery rate of single pregnancies by more than 50% within 48 hours of starting administration.

These data were presented at the 2021 Royal College of Obstetrics and Gynecology Virtual World Congress.

Shares of the biopharmaceutical company rose more than 3% during Thursday's recent pre-market event. ObsEva (OBSV) said on Thursday that data from its proof-of-concept trial showed the potential of ebopiprant as a treatment for spontaneous premature births.

In a phase 2a study, ebopiprant was found to be well tolerated and has shown early evidence of efficacy. The statement said that compared to using Atosiban alone, the candidate drug for injecting premature women with atosiban reduced the delivery rate of single pregnancies by more than 50% within 48 hours of starting administration.

These data were presented at the 2021 Royal College of Obstetrics and Gynecology Virtual World Congress.

Shares of the biopharmaceutical company rose more than 3% during Thursday's recent pre-market event.